Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Physostigmine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 14/20 | 1.00 |
| ▸ | BCHE | P06276 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.92 |
| ▸ | HPGD | P15428 | 2/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Physostigmine SCHEMBL29482277 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| (+)-Physostigmine SCHEMBL15677750 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL4104619 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL24044 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL8800695 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL24045 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL13930339 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL7581686 | 0.99 | ACHE (0.98) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL7581684 | 0.99 | ACHE (0.98) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL7587896 | 0.99 | ACHE (0.98) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190054067-A1 | COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE-LIKE BEHAVIOR IN A SUBJECT | SAINT JOSEPH'S UNIVERSITY | 2019-02-21 | — | — | US | disclosed |
| US-20190054067-A1 | COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE-LIKE BEHAVIOR IN A SUBJECT | SAINT JOSEPH'S UNIVERSITY | 2019-02-21 | — | — | US | disclosed |
| US-20120010283-A1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010283-A1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-8003693-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003693-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090048337-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048337-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-19 | — | — | US | disclosed |
| US-7176201-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176201-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048337-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | FAAH, FAAH2, CNR2 | ACHE 185/4885BCHE 305/4885KDM4E 919/4885 |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | ACHE 18/4885BCHE 42/4885KDM4E 2095/4885 |
| US-20190054067-A1 | COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE-LIKE BEHAVIOR IN A SUBJECT | CHRNA4, CHRNA5, CHRNE | ACHE 42/4885BCHE 300/4885KDM4E 611/4885 |
| US-20120010283-A1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | FAAH, FAAH2, CNR2 | ACHE 189/4885BCHE 295/4885KDM4E 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.